Cartesian Therapeutics, Inc. Common Stock
RNACStock
$8.33−36.08%52W
Market Cap$251.51M
P/E—
Div yield—
Beta0.60
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)2.40%
Price vs S&P 500 (4W)-4.69%
VGM Score24.03
Market Capitalization$251.51M
Earnings Surprise History
Q1 26-1.46est. -0.90
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.13
4.20
4.29
4.29
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
RNACCartesian Therapeutics, Inc. Common Stock | F | F | C | $8.33 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Cartesian Therapeutics is a clinical-stage biopharmaceutical company developing mRNA-based therapies to induce immune tolerance. The company's ImmTOR platform uses proprietary manufacturing and cellular engineering technology to mitigate unwanted immune responses, particularly in autoimmune and transplant-related conditions. This approach represents a novel mechanism for treating conditions where immune suppression needs to be targeted rather than systemic.